78.5 F
San Fernando
Wednesday, Jun 7, 2023

Amgen to Pay Milestone

Biopharmaceutical company Amgen Inc. will pay licensing partner Biopharmaceutical Medarex Inc. an unspecified payment after an antibody moved into clinical trials. Amgen created the antibody using Medarex’s UltiMab technology. Medarex said it could receive future milestone payments and some royalties if the antibody receives approval and moves to the market.

Featured Articles

Related Articles